![]() |
Name |
Hypoxylonol C
|
Molecular Formula | C20H16O5 | |
IUPAC Name* |
(11R,17S,19S)-7,15,17,19-tetrahydroxypentacyclo[10.7.1.02,11.03,8.016,20]icosa-1,3(8),4,6,12(20),13,15-heptaen-9-one
|
|
SMILES |
C1[C@@H](C2=C(C=CC3=C2C(=C4[C@@H]3CC(=O)C5=C4C=CC=C5O)[C@H]1O)O)O
|
|
InChI |
InChI=1S/C20H16O5/c21-11-3-1-2-9-16-10(6-13(23)17(9)11)8-4-5-12(22)19-14(24)7-15(25)20(16)18(8)19/h1-5,10,14-15,21-22,24-25H,6-7H2/t10-,14+,15+/m1/s1
|
|
InChIKey |
PBYZCDIEUANPBF-ONERCXAPSA-N
|
|
Synonyms |
Hypoxylonol C; CHEMBL1950968
|
|
CAS | NA | |
PubChem CID | 57333865 | |
ChEMBL ID | CHEMBL1950968 |
Chemical Classification: |
|
|
---|
Molecular Weight: | 336.3 | ALogp: | 1.0 |
HBD: | 4 | HBA: | 5 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 98.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 25 | QED Weighted: | 0.592 |
Caco-2 Permeability: | -4.989 | MDCK Permeability: | 0.00000847 |
Pgp-inhibitor: | 0.004 | Pgp-substrate: | 0.995 |
Human Intestinal Absorption (HIA): | 0.178 | 20% Bioavailability (F20%): | 0.626 |
30% Bioavailability (F30%): | 0.839 |
Blood-Brain-Barrier Penetration (BBB): | 0.043 | Plasma Protein Binding (PPB): | 93.74% |
Volume Distribution (VD): | 0.876 | Fu: | 7.86% |
CYP1A2-inhibitor: | 0.08 | CYP1A2-substrate: | 0.87 |
CYP2C19-inhibitor: | 0.307 | CYP2C19-substrate: | 0.814 |
CYP2C9-inhibitor: | 0.651 | CYP2C9-substrate: | 0.963 |
CYP2D6-inhibitor: | 0.103 | CYP2D6-substrate: | 0.327 |
CYP3A4-inhibitor: | 0.448 | CYP3A4-substrate: | 0.651 |
Clearance (CL): | 10.552 | Half-life (T1/2): | 0.111 |
hERG Blockers: | 0.039 | Human Hepatotoxicity (H-HT): | 0.188 |
Drug-inuced Liver Injury (DILI): | 0.779 | AMES Toxicity: | 0.316 |
Rat Oral Acute Toxicity: | 0.914 | Maximum Recommended Daily Dose: | 0.963 |
Skin Sensitization: | 0.335 | Carcinogencity: | 0.79 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.112 |
Respiratory Toxicity: | 0.788 |